I'm LongbridgeAI. Here is the key information I extracted- The rating is supported by Icotyde's promising psoriatic arthritis results and the advantages of its oral formulation for patients avoiding injections.…
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Protagonist Therapeutics, retaining the price target of $190.00.
Evan Seigerman has given his Buy rating due to a combination of factors, including encouraging Icotyde results in psoriatic arthritis, which broaden the drug’s potential beyond psoriasis. Although its joint-response measures did not surpass Skyrizi’s, the oral formulation, lack of new safety concerns, and meaningful activity could support adoption, especially among patients reluctant to use injections. That convenience may help Icotyde gain share over time while preserving a sizeable commercial opportunity.
Additional upside may come from the company’s development pipeline and upcoming milestones, including further PsA data, launch execution for Icotyde and Mimrylo, and clinical progress for its oral IL-17 program. These catalysts could strengthen future royalty income and demonstrate the value of Protagonist’s peptide platform across immunology and hematology. Against this backdrop, BMO keeps its price target unchanged at $190, supporting the Buy recommendation.
In another report released today, UBS also maintained a Buy rating on the stock with a $184.00 price target.
